Fig. 5 | Scientific Reports

Fig. 5

From: Topical application of the HSP90 inhibitor 17-AAG reduces skin inflammation and partially restores microbial balance: implications for atopic dermatitis therapy

Fig. 5

Therapeutic treatment with topically applied 17-AAG reduces disease activity in an experimental mouse model of DNCB-induced human-like AD. (a) Schematic representation of the experimental design. AD-like skin inflammation was induced in female BALB/c mice by applying dinitrochlorobenzene (DNCB) to the shaved and depilated back skin (day − 1) as follows: 2% DNCB on day 0, followed by 0.5% DNCB on days 3, 6, 8, 10, 13, 15 and 17. 17-AAG (0.1 µM) or vehicle (DMSO: acetone, 1:40 vol/vol) was applied daily, with a 2-hour interval following DNCB application. (b) Representative images of vehicle- and 17-AAG-treated mice, and clinical disease severity, represented by the cumulative SCORAD index at day 20. Data are expressed as mean ± SEM (with individual values) from one experiment. * P < 0.05.

Back to article page